The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth

被引:38
|
作者
Montgomery, Elizabeth T. [1 ]
Atujuna, Millicent [2 ]
Krogstad, Emily [1 ]
Hartmann, Miriam [1 ]
Ndwayana, Sheily [2 ]
O'Rourke, Shannon [1 ]
Bekker, Linda-Gail [2 ]
van der Straten, Ariane [1 ,3 ]
Minnis, Alexandra M. [1 ,4 ]
机构
[1] RTI Int, Ctr Global Hlth SSES, Womens Global Hlth Imperat, San Francisco Project Off, San Francisco, CA USA
[2] Desmond Tutu HIV Res Ctr, Cape Town, South Africa
[3] Univ Calif San Francisco, Ctr AIDS Prevent Studies, Dept Med, San Francisco, CA 94143 USA
[4] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA
关键词
South Africa; youth; PrEP; sustained-release long-acting PrEP; implants; injections; DAPIVIRINE VAGINAL RING; PREVENTION; ACCEPTABILITY; TRIAL;
D O I
10.1097/QAI.0000000000001960
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Long-acting injectable and implantable approaches aim to overcome some of the documented challenges with uptake and adherence to current HIV prevention methods. Youth are a key end-user population for these methods. We used qualitative methods to examine product attributes and preferences for current and future long-acting HIV prevention approaches. Methods: Ninety-five South African youth aged 18-24 years, of whom 62 were female and 33 male, completed 50 interviews and 6 focus groups. We purposively selected for previous product experience, including oral pre-exposure prophylaxis, injectable pre-exposure prophylaxis, or the vaginal ring, to ensure participants' opinions were rooted in actual experience. Results: Irrespective of previous method-use experience, gender, or sexual orientation, the majority expressed a preference for prevention methods formulated as injectables or implants. Several mentioned that their top priority in any product was efficacy, and for some, this overrode other concerns; for example, even if they feared pain, an implant or an injectable would be used if fully protective. Although efficacy was a top priority, there was also a clear desire across all subgroups for a product that would not interfere with sex, would stay in the system to provide protection, and that caused minimal burden, or was not apparent to others, and these characteristics were most salient for long-acting methods. Conclusions: Narrative explanations for preferences converged thematically around different dimensions of "invisibility" including invisibility to oneself, one's partner and household members, and community members. End-user preferences can be used to inform product development of long-acting HIV prevention approaches formulated as injections or implants to optimize adherence and impact.
引用
收藏
页码:542 / 550
页数:9
相关论文
共 50 条
  • [11] Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxis
    Glidden, David V.
    CURRENT OPINION IN HIV AND AIDS, 2020, 15 (01) : 56 - 60
  • [12] Discrete choice experiment on the preferences for long-acting pre-exposure prophylaxis (PrEP) among pregnant women without HIV in Kisumu and Siaya, Kenya
    Concepcion, T.
    Kinuthia, J.
    Abuna, F.
    Akim, E.
    Dettinger, J.
    Gomez, L.
    Mukenyi, E.
    Ngumbau, N.
    Nyabiage, J.
    Ochieng, B.
    Watoyi, S.
    Pintye, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27
  • [13] Long-Acting Injectable Pre-Exposure Prophylaxis Perceptions and Preferences Among Transgender and Nonbinary Young Adults in the United States
    Gordon, Allegra R.
    Haiken, Samantha
    Murchison, Gabriel R.
    Agenor, Madina
    Hughto, Jaclyn M. W.
    Nelson, Kimberly M.
    QUALITATIVE HEALTH RESEARCH, 2025, 35 (01) : 74 - 87
  • [14] Long-Acting Injectable Drugs for HIV-1 Pre-Exposure Prophylaxis: Considerations for Africa
    Moyo, Enos
    Murewanhema, Grant
    Musuka, Godfrey
    Dzinamarira, Tafadzwa
    TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2022, 7 (08)
  • [15] Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States
    Anita J. Brogan
    Ashley E. Davis
    Claire E. Mellott
    Jeremy Fraysse
    Aimee A. Metzner
    Alan K. Oglesby
    PharmacoEconomics, 2024, 42 : 447 - 461
  • [16] Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States
    Brogan, Anita J.
    Davis, Ashley E.
    Mellott, Claire E.
    Fraysse, Jeremy
    Metzner, Aimee A.
    Oglesby, Alan K.
    PHARMACOECONOMICS, 2024, 42 (04) : 447 - 461
  • [17] Pre-exposure prophylaxis of non-HIV viral infections and the role of long-acting antivirals
    Soriano, Vicente
    Moreno-Torres, Victor
    de Mendoza, Carmen
    Fernandez-Montero, Jose V.
    Trevino, Ana
    Corral, Octavio
    de Jesus, Fernando
    Barreiro, Pablo
    AIDS REVIEWS, 2023, 25 (04) : 162 - 172
  • [18] Improving preparedness for introducing and scaling up long-acting HIV pre-exposure prophylaxis in Asia
    Bavinton, Benjamin R.
    Schmidt, Heather-Marie A.
    Mills, Stephen
    Phanuphak, Nittaya
    SEXUAL HEALTH, 2024, 21 (04)
  • [19] Perceptions of the attributes of new long-acting HIV pre-exposure prophylaxis formulations compared with a daily, oral dose among South African young women: a qualitative study
    Shamu, Patience
    Mullick, Saiqa
    Christofides, Nicola J.
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2024, 36 (12): : 1815 - 1825
  • [20] Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis
    Pike, Carey
    Rousseau, Elzette
    Bekker, Linda-Gail
    SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, 2023, 24 (01)